Trading of the shares of the company will resume on 03-Aug-2026.

Trading of the shares of the company will remain suspended on record date i.e., 02-Aug-2026.

Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 29.07.2026 to 30.07.2026 and trading of the shares will remain suspended on record date i.e., 02.08.2026.

Credit Rating Information and Services PLC (CRISL) has assigned the rating of the Company as "AAA" in the long term and "ST-1" for short term along with Stable outlook in consideration of its audited financials up to June 30, 2025 also unaudited financials up to March 31, 2026 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

(Cont. News of BXPHARMA): The Company has also reported Consolidated EPS of Tk. 15.56, Consolidated NAV per share of Tk. 119.04, and Consolidated NOCFPS of Tk. 16.19 for the year ended June 30, 2025, as against Tk. 13.07, Tk. 107.48, and Tk. 18.75 respectively for the year ended June 30, 2024. (end)

There will be no price limit on the trading of the shares of the Company today (24.06.2026) following its corporate declaration.

(Cont. News of BXPHARMA): These factors, together with reduced cash outflows related to working capital, contributed to a favorable deviation in Net Operating Cash Flows Per Share during the reporting period. (end)

(Cont. news of BXPHARMA): These factors, together with reduced cash outflows related to working capital, contributed to the favorable deviation in NOCFPS. (end)

(Q3 Un-audited): Consolidated EPS was Tk. 4.98 for January-March 2026 as against Tk. 3.86 for January-March 2025; Consolidated EPS was Tk. 15.56 for July 2025-March 2026 as against Tk. 11.73 for July 2024-March 2025. Consolidated NOCFPS was Tk. 16.74 for July 2025-March 2026 as against Tk. 9.46 for July 2024-March 2025. Consolidated NAV per share was Tk. 134.60 as on March 31, 2026 and Tk. 115.21 as on March 31, 2025.

The Company has informed that pursuant to the consent obtained from Bangladesh Securities and Exchange Commission vide their letter No. SEC/SRMIC/94-34/Part-X/124 dated June 21, 2026, a meeting of the Board of Directors will be held on June 23, 2026 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.